中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (11): 3124-3143.doi: 10.4103/NRR.NRR-D-24-00642

• 综述:退行性病与再生 • 上一篇    下一篇

铜稳态与神经退行性疾病

  

  • 出版日期:2025-11-15 发布日期:2025-02-22
  • 基金资助:
    国家自然科学基金项目(82160690)、教育部协同创新中心项目(2020-39)、贵州省科技基金项目(ZK[2021]-014)

Copper homeostasis and neurodegenerative diseases

Yuanyuan Wang, Daidi Li, Kaifei Xu, Guoqing Wang, Feng Zhang*   

  1. International Research Laboratory of Ethnomedicine of Ministry of Education, Key Laboratory of Basic Pharmacology of Ministry of Education, Laboratory Animal Center and Key Laboratory of Basic Pharmacology of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou Province, China
  • Online:2025-11-15 Published:2025-02-22
  • Contact: Feng Zhang, PhD, zhangfengzmc@163.com.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 82160690; Collaborative Innovation Center of Chinese Ministry of Education, No. 2020-39; Science and Technology Foundation of Guizhou Province, No. ZK [2021]-014 (all to FZ).

摘要:


铜是人体内含量最丰富的过渡金属之一,大脑的生理活动需要它来维持各种功能在一定浓度范围内正常工作。铜的稳态由一个复杂的铜依赖蛋白网络精心维持,包括铜转运体(CTR1和CTR2)、两种铜离子转运体ATP7A和ATP7B以及3种铜伴侣蛋白(ATOX1,CCS和COX17)。铜平衡紊乱可导致脑组织缺铜或铜蓄积。新的证据表明,异常的铜代谢或铜与各种蛋白质[包括脑磷脂蛋白(CP)和金属硫蛋白(MT)]的结合参与了神经退行性疾病的发病机制,然而,这些过程的确切病理机制尚不清楚。过量的铜是一种强效氧化剂,会增加活性氧的产生并促进氧化应激。活性氧水平升高会进一步损害线粒体的完整性,导致线粒体功能障碍。在铜诱导的神经炎症中,活性氧是关键的信号分子,其水平升高会激活几种关键的炎症通路。此外,铜可与多种神经元蛋白异常结合,包括α-突触核蛋白、tau、超氧化物歧化酶1和亨廷廷蛋白(HTT),从而诱发神经毒性并最终导致细胞死亡。文章重点介绍评估铜在神经退行性疾病中作用的最新文献研究成果,尤其关注含铜金属酶和铜结合蛋白在调节铜稳态中的作用及其在神经退行性疾病发病机制中的参与。文章通过综合目前关于铜在氧化应激、神经炎症、线粒体功能障碍和蛋白质错误折叠中的功能的研究成果,阐明了铜导致各种遗传性和神经元疾病的病理机制、如威尔逊病、门克斯综合征、阿尔茨海默病、帕金森病、肌萎缩侧索硬化、亨廷顿病和多发性硬化。文章还进一步讨论了具有临床意义的潜在治疗靶点,包括铜锌依赖性酶超氧化物歧化酶 1(SOD1)、D-青霉胺(DPA)和5,7-二氯-2-[(二甲基氨基)甲基]-8-羟基喹啉(PBT2),以及与之相关的治疗药物。总之,铜稳态是神经退行性疾病的潜在病因,文章结果为基于铜稳态预防和治疗神经退行性疾病提供了新的见解。

https://orcid.org/0000-0003-1122-3640 (Feng Zhang) 

关键词: 阿尔茨海默病, 肌萎缩侧索硬化, 铜稳态, 铜毒性, 亨廷顿病, 门克斯综合征, 帕金森病, 多发性硬化, 神经退行性疾病, 威尔逊病

Abstract: Copper, one of the most prolific transition metals in the body, is required for normal brain physiological activity and allows various functions to work normally through its range of concentrations. Copper homeostasis is meticulously maintained through a complex network of copper-dependent proteins, including copper transporters (CTR1 and CTR2), the two copper ion transporters the Cu -transporting ATPase 1 (ATP7A) and Cu-transporting beta (ATP7B), and the three copper chaperones ATOX1, CCS, and COX17. Disruptions in copper homeostasis can lead to either the deficiency or accumulation of copper in brain tissue. Emerging evidence suggests that abnormal copper metabolism or copper binding to various proteins, including ceruloplasmin and metallothionein, is involved in the pathogenesis of neurodegenerative disorders. However, the exact mechanisms underlying these processes are not known. Copper is a potent oxidant that increases reactive oxygen species production and promotes oxidative stress. Elevated reactive oxygen species levels may further compromise mitochondrial integrity and cause mitochondrial dysfunction. Reactive oxygen species serve as key signaling molecules in copper-induced neuroinflammation, with elevated levels activating several critical inflammatory pathways. Additionally, copper can bind aberrantly to several neuronal proteins, including alphasynuclein, tau, superoxide dismutase 1, and huntingtin, thereby inducing neurotoxicity and ultimately cell death. This study focuses on the latest literature evaluating the role of copper in neurodegenerative diseases, with a particular focus on copper-containing metalloenzymes and copper-binding proteins in the regulation of copper homeostasis and their involvement in neurodegenerative disease pathogenesis. By synthesizing the current findings on the functions of copper in oxidative stress, neuroinflammation, mitochondrial dysfunction, and protein misfolding, we aim to elucidate the mechanisms by which copper contributes to a wide range of hereditary and neuronal disorders, such as Wilson’s disease, Menkes’ disease, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple sclerosis. Potential clinically significant therapeutic targets, including superoxide dismutase 1, D-penicillamine, and 5,7-dichloro2-[(dimethylamino)methyl]-8-hydroxyquinoline, along with their associated therapeutic agents, are further discussed. Ultimately, we collate evidence that copper homeostasis may function in the underlying etiology of several neurodegenerative diseases and offer novel insights into the potential prevention and treatment of these diseases based on copper homeostasis.

Key words: Alzheimer’s disease, amyotrophic lateral sclerosis disease, copper homeostasis, copper toxicity, Huntington’s disease, Menkes’ disease, multiple sclerosis, neurodegenerative disease, Parkinson’s disease, Wilson’s disease